September 29, 2016 4:26 AM ET

Healthcare Equipment and Supplies

Company Overview of Acelity L.P. Inc.

Company Overview

Kinetic Concepts Inc. produces surgical healing and hospital patient-mobility equipment, including a tissue-repair therapy used in hospitals in the U.S. and worldwide for acute care and serious trauma. Its wound-care and tissue-repair system is used in pulmonary care, for post-cardiac-arrest complications in the intensive-care unit, and for other types of wound treatment including failed surgical closures, amputations, and serious pressure ulcers. The system works by using a vacuum-assisted closure technology. A second product is a line of hospital equipment that provides mobility to patients who cannot move because of pulmonary complications or due to obesity. Its bariatric-care products pr...

12930 West Interstate 10

San Antonio, TX 78249

United States

Founded in 1976

5,800 Employees



Key Executives for Acelity L.P. Inc.

Chief Executive Officer, President and Director
Age: 50
Interim Chief Financial Officer
Senior Vice President of Operations, Quality & Regulatory
Age: 57
President of Developed Markets
Age: 46
Group President of Businesses & Innovation
Age: 42
Compensation as of Fiscal Year 2016.

Acelity L.P. Inc. Key Developments

Acelity L.P. Inc. Announces Management Changes

Acelity L.P. Inc. announced that Tom Casey, Executive Vice President and Chief Financial Officer for Acelity, has resigned from his role at Acelity, effective September 16 in order to accept another employment opportunity. Todd Wyatt, Vice President, Global Corporate Finance, will serve as interim CFO while Acelity conducts the formal process of identifying Casey’s successor. Wyatt joined the company in 2004 and has previously served as Vice President, Global Corporate Finance, overseeing the financial operations for Acelity.

Acelity Launches PREVENA PLUS™ Incision Management System with Customizable Dressing for Range of Complex Procedures

Acelity announced the expansion of its PREVENA™ Therapy portfolio with the global launch of the PREVENA PLUS™ Incision Management System. The PREVENA PLUS™ System offers the proven effectiveness of closed incision negative pressure therapy (ciNPT) with improved versatility, portability, and flexibility. PREVENA™ Therapy helps hold incision edges together and protects incisions from external infectious sources, and the new PREVENA PLUS™ System, now available in the United States and various global markets, includes a Customizable Dressing designed for linear, non-linear, and intersecting incisions up to 90cm in length. The PREVENA PLUS™ Incision Management System is designed specifically for the management of surgical incisions that continue to drain following sutured or stapled closure. The System enables clinicians to manage incisions up to 90 cm in length with an adjustable dressing, and allows a surgeon to apply PREVENA™ Therapy following a number of procedures including laparotomy, panniculectomy, spinal fusion, revision hip and knee arthroplasty and lower extremity trauma fracture. It uses a foam bolster to provide negative pressure at -125mmHg for up to seven days and patented SENSAT.R.A.C™ Technology that monitors and maintains pressure at the incision site. It includes a replaceable 150ml canister to keep exudates away from the incision site. PREVENA™ Therapy covers and protects incisions from external contamination, while negative pressure removes fluid and infectious material from the site. PREVENA™ Therapy Systems are optimized for patient safety with visual and audible alarms and ionic silver within the interface layer designed to reduce bacterial colonization in the fabric.

Acelity Introduces New Product

Acelity has introduced a new product nationally that will make it less painful for patients to change their wound dressings. The Biosorb Gelling Fiber Dressing forms a gel when it comes into contact with an open wound. The gel offers increased absorbency and holds its shape, which allows for intact removal of the dressing. It can be used on a wide range of open wounds, such as leg ulcers, pressure ulcers, diabetic foot ulcers, open surgical wounds, partial thickness burns, traumatic wounds and cancer-related wounds. Such chronic and surgical wounds affect more than 10.5 million people in the United States and Europe. The Biosorb product also will be available in Europe in the coming months. Acelity, which employs 1,500 people at its San Antonio headquarters, specializes in advanced wound care and regenerative medicine.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

December 1, 2015
Spiracur Inc., SNaP® Therapy System

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Bloomberg L.P. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Acelity L.P. Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at